4,7-dichloro-3-hydrazinylindol-2-one | 23872-21-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4,7-dichloro-3-hydrazinylindol-2-one
• CAS: 23872-21-1
• 化学式: C₈H₅Cl₂N₃O
• 分子量: 230.053
• InChiKey: JTGMKNXRGNCEOW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.61
• 重原子数：
  14.0
• 可旋转键数：
  0.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.48
• 氢给体数：
  2.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  4,7-dichloro-3-hydrazinylindol-2-one 、 邻香草醛 以 甲醇 为溶剂， 反应 3.0h， 以0.28 g的产率得到2-hydroxy,3-methoxybenzaldehyde-N-(4,7-dichloro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)hydrazone
  参考文献：
  名称：

  Synthesis of bis-Schiff bases of isatins and their antiglycation activity

  摘要：

  Bis-Schiff bases 1-27 have been synthesized and their in vitro antiglycation potential has been evaluated. Compounds 21 (IC50 = 243.95 +/- 4.59 mu M), 20 (IC50 = 257.61 +/- 5.63 mu M), and 7 (IC50 = 291.14 +/- 2.53 mu M) showed an excellent antiglycation activity better than the standard (rutin, IC50 = 294.46 +/- 1.50 mu M). This study has identified a series of potential molecules as antiglycation agents. A structure-activity relationship has been studied, and all the compounds were characterized by spectroscopic techniques. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.09.028
• 作为产物：
  描述：

  4,7-二氯吲哚满二酮 在 一水合肼 作用下， 反应 0.42h， 生成 4,7-dichloro-3-hydrazinylindol-2-one
  参考文献：
  名称：

  Synthesis of bis-Schiff bases of isatins and their antiglycation activity

  摘要：

  Bis-Schiff bases 1-27 have been synthesized and their in vitro antiglycation potential has been evaluated. Compounds 21 (IC50 = 243.95 +/- 4.59 mu M), 20 (IC50 = 257.61 +/- 5.63 mu M), and 7 (IC50 = 291.14 +/- 2.53 mu M) showed an excellent antiglycation activity better than the standard (rutin, IC50 = 294.46 +/- 1.50 mu M). This study has identified a series of potential molecules as antiglycation agents. A structure-activity relationship has been studied, and all the compounds were characterized by spectroscopic techniques. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.09.028

文献信息

• Indolinone hydrazides as c-Met inhibitors
  申请人：Koenig Marcel

  公开号：US20060009493A1

  公开（公告）日：2006-01-12

  The present invention relates to compounds of the formulae (I)-(XII), wherein R 1 -R 71 , A, B, X, Y, G, L and Z are defined herein, and their pharmaceutically acceptable salts. These compounds modulate the activity of c-Met and are therefore expected to be useful in the prevention and treatment of c-Met related disorders such as cancer.

  本发明涉及式(I)-(XII)的化合物，其中R1-R71、A、B、X、Y、G、L和Z在此定义，并且它们的药学上可接受的盐。这些化合物调节c-Met的活性，因此预计在预防和治疗与c-Met相关的疾病，如癌症方面有用。
• Khan, Khalid Mohammed; Khan, Momin; Ali, Muhammad, Journal of the Chemical Society of Pakistan, 2013, vol. 35, # 3, p. 987 - 993
  作者：Khan, Khalid Mohammed、Khan, Momin、Ali, Muhammad、Qadir, Muhammad Irfan、Perveen, Shahnaz、Karim, Aneela、Choudhary, Muhammad Iqbal

  DOI：——

  日期：——
• Synthesis of bis-Schiff bases of isatins and their antiglycation activity
  作者：Khalid Mohammed Khan、Momin Khan、Muhammad Ali、Muhammad Taha、Saima Rasheed、Shahnaz Perveen、M. Iqbal Choudhary

  DOI：10.1016/j.bmc.2009.09.028

  日期：2009.11

  Bis-Schiff bases 1-27 have been synthesized and their in vitro antiglycation potential has been evaluated. Compounds 21 (IC50 = 243.95 +/- 4.59 mu M), 20 (IC50 = 257.61 +/- 5.63 mu M), and 7 (IC50 = 291.14 +/- 2.53 mu M) showed an excellent antiglycation activity better than the standard (rutin, IC50 = 294.46 +/- 1.50 mu M). This study has identified a series of potential molecules as antiglycation agents. A structure-activity relationship has been studied, and all the compounds were characterized by spectroscopic techniques. (C) 2009 Elsevier Ltd. All rights reserved.
• INDOLINONE HYDRAZIDES AS C-MET INHIBITORS
  申请人：Sugen, Inc.

  公开号：EP1644362A2

  公开（公告）日：2006-04-12
• [EN] INDOLINONE HYDRAZIDES AS C-MET INHIBITORS<br/>[FR] HYDRAZIDES D'INDOLINONE UTILISES EN TANT QU'INHIBITEURS DU RECEPTEUR C-MET
  申请人：SUGEN INC

  公开号：WO2005005378A2

  公开（公告）日：2005-01-20

  The present invention relates to compounds of the formulae (I) - (XII), wherein R1 - R71, A, B, X, Y, G, L and Z are defined herein, and their pharmaceutically acceptable salts. These compounds modulate the activity of c-Met and are therefore expected to be useful in the prevention and treatment of c-Met related disorders such as cancer.